Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis.

Ziliotto N, Baroni M, Straudi S, Manfredini F, Mari R, Menegatti E, Voltan R, Secchiero P, Zamboni P, Basaglia N, Marchetti G, Bernardi F.

Front Neurol. 2018 Apr 20;9:245. doi: 10.3389/fneur.2018.00245. eCollection 2018.

2.

Novel Compliant Scaffold with Specific Design for Venous System: Results of a Porcine Model Study.

Veroux P, Giaquinta A, Virgilio C, Zani DD, Ravasio G, Ardita V, Secchiero P, Scanziani E, Zamboni P, Veroux M.

Biomed Res Int. 2018 Jan 31;2018:7312315. doi: 10.1155/2018/7312315. eCollection 2018.

3.

Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases.

Tisato V, Zuliani G, Vigliano M, Longo G, Franchini E, Secchiero P, Zauli G, Paraboschi EM, Vikram Singh A, Serino ML, Ortolani B, Zurlo A, Bosi C, Greco A, Seripa D, Asselta R, Gemmati D.

PLoS One. 2018 Mar 8;13(3):e0193867. doi: 10.1371/journal.pone.0193867. eCollection 2018.

4.

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

Bernardi S, Toffoli B, Tisato V, Bossi F, Biffi S, Lorenzon A, Zauli G, Secchiero P, Fabris B.

Clin Sci (Lond). 2018 Jan 5;132(1):69-83. doi: 10.1042/CS20171221. Print 2018 Jan 16.

PMID:
29167318
5.

Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women.

Tisato V, Secchiero P, Bonaccorsi G, Bergamini C, Greco P, Zauli G, Cervellati C.

Mediators Inflamm. 2017;2017:5356020. doi: 10.1155/2017/5356020. Epub 2017 Sep 5.

6.

The calendar of cytokines: Seasonal variation of circulating cytokines in chronic venous insufficiency.

Spath P, Tisato V, Gianesini S, Tessari M, Menegatti E, Manfredini R, Occhionorelli S, Secchiero P, Zamboni P.

JRSM Cardiovasc Dis. 2017 Sep 8;6:2048004017729279. doi: 10.1177/2048004017729279. eCollection 2017 Jan-Dec.

7.

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.

Secchiero P, Voltan R, Rimondi E, Melloni E, Athanasakis E, Tisato V, Gallo S, Rigolin GM, Zauli G.

Oncotarget. 2017 Jul 22;8(35):59235-59245. doi: 10.18632/oncotarget.19494. eCollection 2017 Aug 29.

8.

Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.

D'Abundo L, Callegari E, Bresin A, Chillemi A, Elamin BK, Guerriero P, Huang X, Saccenti E, Hussein EMAA, Casciano F, Secchiero P, Zauli G, Calin GA, Russo G, Lee LJ, Croce CM, Marcucci G, Sabbioni S, Malavasi F, Negrini M.

Oncogene. 2017 Nov 23;36(47):6617-6626. doi: 10.1038/onc.2017.269. Epub 2017 Aug 7.

9.

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.

Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G.

J Hematol Oncol. 2017 Jul 3;10(1):133. doi: 10.1186/s13045-017-0500-5. Review.

10.

Association between thyroid hormones and TRAIL.

Bernardi S, Bossi F, Toffoli B, Giudici F, Bramante A, Furlanis G, Stenner E, Secchiero P, Zauli G, Carretta R, Fabris B.

Clin Biochem. 2017 Nov;50(16-17):972-976. doi: 10.1016/j.clinbiochem.2017.05.011. Epub 2017 May 25.

11.

Context-dependent function of ROS in the vascular endothelium: The role of the Notch pathway and shear stress.

Vieceli Dalla Sega F, Aquila G, Fortini F, Vaccarezza M, Secchiero P, Rizzo P, Campo G.

Biofactors. 2017 Jul 8;43(4):475-485. doi: 10.1002/biof.1359. Epub 2017 Apr 17. Review.

PMID:
28419584
12.

The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressIve MultiplE sclerosis patients (RAGTIME): study protocol for a randomized controlled trial.

Straudi S, Manfredini F, Lamberti N, Zamboni P, Bernardi F, Marchetti G, Pinton P, Bonora M, Secchiero P, Tisato V, Volpato S, Basaglia N.

Trials. 2017 Feb 27;18(1):88. doi: 10.1186/s13063-017-1838-2.

13.

Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential.

Färkkilä A, Zauli G, Haltia UM, Pihlajoki M, Unkila-Kallio L, Secchiero P, Heikinheimo M.

Tumour Biol. 2016 Sep;37(9):11909-11916. Epub 2016 Apr 11.

PMID:
27067438
14.

Multimodal near-infrared-emitting PluS Silica nanoparticles with fluorescent, photoacoustic, and photothermal capabilities.

Biffi S, Petrizza L, Garrovo C, Rampazzo E, Andolfi L, Giustetto P, Nikolov I, Kurdi G, Danailov MB, Zauli G, Secchiero P, Prodi L.

Int J Nanomedicine. 2016 Sep 22;11:4865-4874. eCollection 2016.

15.

Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity.

Voltan R, Secchiero P, Casciano F, Milani D, Zauli G, Tisato V.

Int J Biochem Cell Biol. 2016 Dec;81(Pt B):364-374. doi: 10.1016/j.biocel.2016.09.019. Epub 2016 Sep 26. Review.

16.

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.

Voltan R, Rimondi E, Melloni E, Rigolin GM, Casciano F, Arcidiacono MV, Celeghini C, Cuneo A, Zauli G, Secchiero P.

Oncotarget. 2016 Oct 25;7(43):70623-70638. doi: 10.18632/oncotarget.12139.

17.

Oscillatory flow suppression improves inflammation in chronic venous disease.

Zamboni P, Spath P, Tisato V, Tessari M, Dalla Caneva P, Menegatti E, Occhionorelli S, Gianesini S, Secchiero P.

J Surg Res. 2016 Sep;205(1):238-45. doi: 10.1016/j.jss.2016.06.046. Epub 2016 Jun 25.

PMID:
27621026
18.

Serum Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Levels in Older Subjects with Dementia and Mild Cognitive Impairment.

Tisato V, Rimondi E, Brombo G, Volpato S, Zurlo A, Zauli G, Secchiero P, Zuliani G.

Dement Geriatr Cogn Disord. 2016;41(5-6):273-80. doi: 10.1159/000446275. Epub 2016 Jun 16.

19.

Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells.

Pannella M, Caliceti C, Fortini F, Aquila G, Vieceli Dalla Sega F, Pannuti A, Fortini C, Morelli MB, Fucili A, Francolini G, Voltan R, Secchiero P, Dinelli G, Leoncini E, Ferracin M, Hrelia S, Miele L, Rizzo P.

J Cell Physiol. 2016 Dec;231(12):2700-10. doi: 10.1002/jcp.25373. Epub 2016 Apr 4.

20.

Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1.

Voltan R, Rimondi E, Melloni E, Gilli P, Bertolasi V, Casciano F, Rigolin GM, Zauli G, Secchiero P.

Oncotarget. 2016 Apr 5;7(14):18965-77. doi: 10.18632/oncotarget.7879.

21.

Clinical perspectives of TRAIL: insights into central nervous system disorders.

Tisato V, Gonelli A, Voltan R, Secchiero P, Zauli G.

Cell Mol Life Sci. 2016 May;73(10):2017-27. doi: 10.1007/s00018-016-2164-7. Epub 2016 Feb 24. Review.

22.

Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.

Trapella C, Voltan R, Melloni E, Tisato V, Celeghini C, Bianco S, Fantinati A, Salvadori S, Guerrini R, Secchiero P, Zauli G.

J Med Chem. 2016 Jan 14;59(1):147-56. doi: 10.1021/acs.jmedchem.5b01165. Epub 2015 Dec 23.

PMID:
26653539
23.

Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy.

Tisato V, Perri P, Rimondi E, Melloni E, Lamberti G, Milani D, Secchiero P, Zauli G.

Mediators Inflamm. 2015;2015:942948. doi: 10.1155/2015/942948. Epub 2015 Oct 7.

24.

Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery.

Biffi S, Voltan R, Rampazzo E, Prodi L, Zauli G, Secchiero P.

Expert Opin Drug Deliv. 2015;12(12):1837-49. doi: 10.1517/17425247.2015.1071791. Epub 2015 Aug 9. Review.

PMID:
26289673
25.

MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC.

Joshi P, Jeon YJ, Laganà A, Middleton J, Secchiero P, Garofalo M, Croce CM.

Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8650-5. doi: 10.1073/pnas.1500886112. Epub 2015 Jun 29.

26.

Correction: MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.

Garofalo M, Jeon YJ, Nuovo GJ, Middleton J, Secchiero P, Joshi P, Alder H, Nazaryan N, Di Leva G, Romano G, Crawford M, Nana-Sinkam P, Croce CM.

PLoS One. 2015 Jun 25;10(6):e0131729. doi: 10.1371/journal.pone.0131729. eCollection 2015. No abstract available.

27.

A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.

Jeon YJ, Middleton J, Kim T, Laganà A, Piovan C, Secchiero P, Nuovo GJ, Cui R, Joshi P, Romano G, Di Leva G, Lee BK, Sun HL, Kim Y, Fadda P, Alder H, Garofalo M, Croce CM.

Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):E3355-64. doi: 10.1073/pnas.1504630112. Epub 2015 Jun 15. Erratum in: Proc Natl Acad Sci U S A. 2017 Mar 21;114(12 ):E2542.

28.

Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus.

Tornese G, Tisato V, Monasta L, Vecchi Brumatti L, Zauli G, Secchiero P.

Acta Diabetol. 2015 Oct;52(5):1003-6. doi: 10.1007/s00592-015-0731-2. Epub 2015 Apr 12. No abstract available.

29.

TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.

Perri P, Zauli G, Gonelli A, Milani D, Celeghini C, Lamberti G, Secchiero P.

Biomed Res Int. 2015;2015:424019. doi: 10.1155/2015/424019. Epub 2015 Mar 5. Review.

30.

TRAIL modulates the immune system and protects against the development of diabetes.

Bossi F, Bernardi S, Zauli G, Secchiero P, Fabris B.

J Immunol Res. 2015;2015:680749. doi: 10.1155/2015/680749. Epub 2015 Feb 18. Review.

31.

The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.

Athanasakis E, Melloni E, Rigolin GM, Agnoletto C, Voltan R, Vozzi D, Piscianz E, Segat L, Dal Monego S, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2014 Dec 30;5(24):12635-45.

32.

The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway.

Agnoletto C, Brunelli L, Melloni E, Pastorelli R, Casciano F, Rimondi E, Rigolin GM, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2015 Feb 10;6(4):2385-96.

33.

Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model.

Tisato V, Garrovo C, Biffi S, Petrera F, Voltan R, Casciano F, Meroni G, Agnoletto C, Zauli G, Secchiero P.

PLoS One. 2014 Dec 15;9(12):e115387. doi: 10.1371/journal.pone.0115387. eCollection 2014.

34.

Levels of circulating TNF-related apoptosis-inducing ligand in celiac disease.

Celeghini C, Not T, Norcio A, Monasta L, Secchiero P.

Exp Ther Med. 2014 Dec;8(6):1906-1908. Epub 2014 Oct 15.

35.

Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.

Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, Catena C, Mulatero P, Barbone F, Radillo O, Zauli G, Secchiero P.

Mol Cell Endocrinol. 2014 Aug 25;394(1-2):13-20. doi: 10.1016/j.mce.2014.06.004. Epub 2014 Jul 3.

PMID:
24998520
36.

Ultrastructure of internal jugular vein defective valves.

Zamboni P, Tisato V, Menegatti E, Mascoli F, Gianesini S, Salvi F, Secchiero P.

Phlebology. 2015 Oct;30(9):644-7. doi: 10.1177/0268355514541980. Epub 2014 Jun 27.

37.

Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry.

Cervellati C, Secchiero P, Bonaccorsi G, Celeghini C, Zauli G.

Mediators Inflamm. 2014;2014:306848. doi: 10.1155/2014/306848. Epub 2014 May 21.

38.

Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.

Agnoletto C, Melloni E, Casciano F, Rigolin GM, Rimondi E, Celeghini C, Brunelli L, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2014 Jun 30;5(12):4347-60.

39.

Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival.

Zauli G, Celeghini C, Monasta L, Martinelli M, Luppi S, Gonelli A, Grill V, Ricci G, Secchiero P.

Reproduction. 2014 Aug;148(2):191-8. doi: 10.1530/REP-14-0144. Epub 2014 May 13.

40.

In vitro endothelial cell proliferation assay reveals distinct levels of proangiogenic cytokines characterizing sera of healthy subjects and of patients with heart failure.

Voltan R, Zauli G, Rizzo P, Fucili A, Pannella M, Marci R, Tisato V, Ferrari R, Secchiero P.

Mediators Inflamm. 2014;2014:257081. doi: 10.1155/2014/257081. Epub 2014 Mar 23.

41.

Modulation of circulating cytokine-chemokine profile in patients affected by chronic venous insufficiency undergoing surgical hemodynamic correction.

Tisato V, Zauli G, Gianesini S, Menegatti E, Brunelli L, Manfredini R, Zamboni P, Secchiero P.

J Immunol Res. 2014;2014:473765. doi: 10.1155/2014/473765. Epub 2014 Mar 25.

42.

Inhibitory effect of natural anti-inflammatory compounds on cytokines released by chronic venous disease patient-derived endothelial cells.

Tisato V, Zauli G, Rimondi E, Gianesini S, Brunelli L, Menegatti E, Zamboni P, Secchiero P.

Mediators Inflamm. 2013;2013:423407. doi: 10.1155/2013/423407. Epub 2013 Dec 31.

43.

Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells.

Tisato V, Norcio A, Celeghini C, Milani D, Gonelli A, Secchiero P.

Clinics (Sao Paulo). 2014 Jan;69(1):68-74. doi: 10.6061/clinics/2014(01)10.

44.

Inverse correlation between circulating levels of TNF-related apoptosis-inducing ligand and 17β-estradiol.

Zauli G, Tisato V, Melloni E, Volpato S, Cervellati C, Bonaccorsi G, Radillo O, Marci R, Secchiero P.

J Clin Endocrinol Metab. 2014 Apr;99(4):E659-64. doi: 10.1210/jc.2013-4193. Epub 2014 Jan 21.

PMID:
24446659
45.

GM-CSF exhibits anti-inflammatory activity on endothelial cells derived from chronic venous disease patients.

Tisato V, Secchiero P, Rimondi E, Gianesini S, Menegatti E, Casciano F, Zamboni P, Zauli G.

Mediators Inflamm. 2013;2013:561689. doi: 10.1155/2013/561689. Epub 2013 Nov 13.

46.

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.

Pozzo F, Dal Bo M, Peragine N, Bomben R, Zucchetto A, Rossi F, Degan M, Rossi D, Chiarenza A, Grossi A, Di Raimondo F, Zaja F, Pozzato G, Secchiero P, Gaidano G, Del Poeta G, Zauli G, Fo À R, Guarini A, Gattei V.

J Hematol Oncol. 2013 Nov 5;6:83. doi: 10.1186/1756-8722-6-83.

47.

The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement.

Tornese G, Iafusco D, Monasta L, Agnoletto C, Tisato V, Ventura A, Zauli G, Secchiero P.

Acta Diabetol. 2014 Apr;51(2):239-46. doi: 10.1007/s00592-013-0507-5. Epub 2013 Aug 8.

PMID:
23925693
48.

Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis.

Rampazzo E, Voltan R, Petrizza L, Zaccheroni N, Prodi L, Casciano F, Zauli G, Secchiero P.

Nanoscale. 2013 Sep 7;5(17):7897-905. doi: 10.1039/c3nr02563b.

PMID:
23851463
49.

MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.

Garofalo M, Jeon YJ, Nuovo GJ, Middleton J, Secchiero P, Joshi P, Alder H, Nazaryan N, Di Leva G, Romano G, Crawford M, Nana-Sinkam P, Croce CM.

PLoS One. 2013 Jun 21;8(6):e67581. doi: 10.1371/journal.pone.0067581. Print 2013.

50.

The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newborns.

Zauli G, Monasta L, Vecchi Brumatti L, Agnoletto C, Volpi P, Secchiero P.

Cytokine. 2013 Oct;64(1):51-3. doi: 10.1016/j.cyto.2013.05.005. Epub 2013 May 27.

PMID:
23722000

Supplemental Content

Loading ...
Support Center